MHP 133 |
Katalog-Nr.GC30446 |
MHP 133 ist ein Medikament mit mehreren ZNS-Zielen und hemmt Acetylcholinesterase (AChE) mit Ki von 69 μM; auch aktiv gegen muskarinische M1- und M2-Rezeptoren, Serotonin-5HT4-Rezeptoren und Imidazol-I2-Rezeptoren.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 147340-43-0
Sample solution is provided at 25 µL, 10mM.
a drug with multiple CNS targets, and inhibits acetylcholinesterase (AChE) with Ki of 69 μM; also active against muscarinic M1 and M2 receptors, serotonin 5HT4 receptors, and imidazole I2 receptors.
MHP-133 is be active (>50% displacement or activity) against muscarinic M1 and M2 receptors, serotonin 5HT4 receptors, and imidazole I2 receptors. MHP-133 exhibits this nicotinic-like activity in the cell line. Although the ED50 for inducing TrkA expression is only about 1 μM, it does predicts the cytoprotective action of MHP-133 in differentiated PC-12 cells deprived of growth factor for 24 h. MHP-133 (10-100 μM) significantly increases the levels of sAPP from cultured astrocytes by 40-60%. MHP-133 produces a bi-phasic effect on slice survival, particularly in the dentate gyrus and the CA1 regions[1].
In rats, MHP-133 (50, 100, or 200 μg/kg, i.p.) enhances acquisition of the task and increases task accuracy. MHP-133 elicits significant improvements in task accuracies during sessions initiated 10 min after dosing[1].
[1]. Buccafusco JJ, et al. MHP-133, a drug with multiple CNS targets: potential for neuroprotection and enhanced cognition. Neurochem Res. 2007 Jul;32(7):1224-37. Epub 2007 Apr 3.
Average Rating: 5
(Based on Reviews and 2 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *